Marcus Butler, M.D., Dana-Farber Cancer Institute (image) Dana-Farber Cancer Institute Share Print E-Mail Caption Marcus Butler, M.D., and his Dana-Farber colleagues report they have developed a technique -- a form of "adoptive immunotherapy" -- that can enable anti-tumor T cells to survive in melanoma patients' bloodstreams for well over a year, in some cases. The results represent the longest that injected anti-tumor T cells have ever endured in cancer patients without the use of supplemental treatments. Credit Sam Ogden Usage Restrictions None Share Print E-Mail Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.